Answer

IFF Scent recovery drivers, 2H evolution for Fine Fragrance vs Consumer Fragrance, and R&D plan to support 2027

1) Drivers of Scent’s recovery

Based on IFF’s commentary and segment reporting, the Scent turnaround is being driven by (a) stronger Fragrance Ingredients performance, (b) stabilization and managed volatility in Fine Fragrance (including the Middle East impact), and (c) rebuilding R&D capability and commercial execution in Consumer Fragrance.

A. Fragrance Ingredients as a near-term earnings tailwind (and then a mix shift)

In Q2, the Scent team delivered 8% sales growth, with a key driver being Fragrance Ingredients growing “north of 20%”. ¹
Management attributes part of the Q2 strength to the year-over-year comparison (“comparing to a down 10% or more in the year ago period”) and part to strategic use of the synthetics portfolio to capture more sales amid macro/supply chain pressures (including higher Brent crude). ¹
They expect this ingredient growth to normalize going forward, with growth shifting towards higher value-added ingredients vs traditional synthetics, and that this shift will take time (with the competitive positioning improving into the next year and “the year after”). ²
On “input costs” (raw materials, energy, logistics), management expects increases that are most impactful in Scent, with energy and logistics being the biggest components, and that customer surcharges may have some lag in Scent. ³

Interpretation: The recovery is not only demand-driven; it also reflects strategic portfolio deployment and normalization dynamics in Fragrance Ingredients—strong in Q2, then deliberately moving toward higher-value ingredients over time. ¹²

B. Fine Fragrance stabilization through volatility management; Q3 softness, Q4 recovery

For Fine Fragrance in Q2, IFF says the team managed the Middle East challenges, finishing slightly positive versus expectations for mid-single-digit decline. ¹
For the remainder of the year, management frames Q3 as softer (including a “20% comparable” because Q3 last year grew 20%), with recovery more evident in Q4. ¹

Interpretation: Fine Fragrance recovery is tied to (1) successful execution under geopolitical volatility and (2) cycling difficult prior-year comps, with improvement expected later in the year. ¹

C. Consumer Fragrance recovery via R&D capability rebuild + go-to-market and market share gains

Management explicitly links the Consumer Fragrance outlook to rebuilding capabilities: they cite that the team has “done a good job on the compounds,” rebuilding R&D capability and go-to-market approach with customers, and “trying to drive market share gains.” ²
In Q2, Consumer Fragrance growth was high single-digit, but management expects normalization toward a low single-digit growth run-rate “on a go-forward basis.” ²

Interpretation: Consumer Fragrance improvement is described as a capability-and-execution recovery (R&D + customer go-to-market + market share), not just a one-quarter bounce. ²

D. R&D capability and pipeline reset is central to the recovery narrative

Management states that 2.5 years ago the R&D pipeline was “not what it should have been,” while today they believe they have a very strong R&D capability, including great perfumers and an “absolutely leading-edge” pipeline of molecules and delivery systems. ⁴
They also emphasize ongoing work: while progress is strong, they are “not satisfied” and continue to strengthen strengths and address gaps. ⁴

Interpretation: The “recovery” framing is directly connected to restoring R&D productivity and pipeline quality, which supports both Fine Fragrance and Consumer Fragrance competitiveness through 2027. ⁴

2) How Fine Fragrance and Consumer Fragrance will evolve in the second half (2H 2026)

Fine Fragrance: mid-single-digit 2H growth, with Q3 softer and Q4 stronger

IFF suggests Fine Fragrance will be a little bit softer in Q3, but stronger in Q4. ²
On a second-half basis, management targets mid-single-digit growth (continuing that trajectory on “strong comparables”). ²
They also reiterate the Middle East-related uncertainty was managed in Q2, and that they are factoring in a softer Q3 and then expect recovery by Q4. ¹

Net expectation for 2H: A recovery profile that looks like Q3 weakness / Q4 rebound, still resulting in mid-single-digit growth for 2H overall. ²¹

Consumer Fragrance: low single-digit 2H growth, normalizing after strong Q2

For Consumer Fragrance, management expects growth in the low single-digit range. ²
They highlight that Q2 was very good (high single-digit), but they expect it will normalize to a low single-digit rate going forward. ²
Management ties this normalization/trajectory to rebuilding R&D capability, compounds work, go-to-market, and market share gains. ²

Net expectation for 2H: Normalization from a strong Q2 print to low single-digit growth as capability gains translate into steadier demand. ²

3) Plan for R&D to support 2027

IFF’s excerpts do not provide a quarter-by-quarter R&D “roadmap” with spending targets, but they do describe the operational plan and what R&D is expected to deliver into 2027.

A. What changed in R&D (capability, pipeline, perfumer output)

Management says that R&D pipeline quality was inadequate 2.5 years ago, but today they have strong R&D capability, “great perfumers” producing leading-edge new Fine Fragrances and Consumer Fragrances, and a pipeline of molecules and delivery systems. ⁴
They also stress the program is still in progress—“not satisfied”—but the direction is strong and gaps are being addressed. ⁴

B. How R&D links to competitive position into 2027 (time horizon)

On Fragrance Ingredients, management states the shift to higher-value natural products is underway, will take more time, and is expected to create a strong competitive position as they move into next year and the year after. ²
While that comment is specifically about ingredients, it supports the broader “into 2027” logic that R&D-enabled product evolution takes time to fully reflect in results. ²

C. R&D is positioned as a key “innovation circle” that supports reinvestment and growth/margins

IFF describes innovation as a “circle” where reinvestment leads to better growth, which then supports margin expansion and continued reinvestment. ⁵
They emphasize maintaining R&D investment intensity, noting the company is in the 8% to 9% range (percentage of sales in R&D) and that reinvestment is “really important” to set themselves apart and drive the growth/margin cycle. ⁵

What this implies for the R&D plan supporting 2027:

Execution focuses on pipeline and perfumer-driven product development in both Fine Fragrance and Consumer Fragrance, with delivery systems and molecule pipeline strengthening now and translating into competitive strength over time. ⁴²
Resourcing is tied to a disciplined reinvestment framework (R&D intensity maintained in an 8% to 9% band) intended to sustain an innovation-led growth and margin path. ⁵

Bottom line summary

Drivers of recovery (Scent): Fragrance Ingredients strength in Q2 plus strategic portfolio leverage, managed Fine Fragrance volatility under Middle East uncertainty, and Consumer Fragrance improvement driven by compounds work plus rebuilt R&D capability and go-to-market execution, all underpinned by a strengthened R&D pipeline. ¹²⁴
2H evolution: Fine Fragrance expected to show Q3 softness / Q4 strength, producing mid-single-digit growth for 2H. ²¹ Consumer Fragrance expected to normalize from Q2 high single-digit to low single-digit for 2H as go-to-market and R&D-led market share gains stabilize. ²
R&D plan for 2027: strengthen R&D capability and pipeline (molecules + delivery systems) after prior underperformance, sustain leading-edge perfumery output across Fine and Consumer, and maintain a deliberate reinvestment “innovation circle” with R&D intensity in the 8%–9% sales range to support durable competitiveness into 2027. ⁴⁵

References

International Flavors & Fragrances Inc. (IFF) earnings transcript 2026 - Q2

Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.

IFF Scent Recovery Driven by Fragrance Ingredients, 2H 2026 Outlook, and 2027 R&D Plan

Sources used

Research question

Answer

IFF Scent recovery drivers, 2H evolution for Fine Fragrance vs Consumer Fragrance, and R&D plan to support 2027

1) Drivers of Scent’s recovery

A. Fragrance Ingredients as a near-term earnings tailwind (and then a mix shift)

B. Fine Fragrance stabilization through volatility management; Q3 softness, Q4 recovery

C. Consumer Fragrance recovery via R&D capability rebuild + go-to-market and market share gains

D. R&D capability and pipeline reset is central to the recovery narrative

2) How Fine Fragrance and Consumer Fragrance will evolve in the second half (2H 2026)

Fine Fragrance: mid-single-digit 2H growth, with Q3 softer and Q4 stronger

Consumer Fragrance: low single-digit 2H growth, normalizing after strong Q2

3) Plan for R&D to support 2027

A. What changed in R&D (capability, pipeline, perfumer output)

B. How R&D links to competitive position into 2027 (time horizon)

C. R&D is positioned as a key “innovation circle” that supports reinvestment and growth/margins

Bottom line summary

References

Keep Reading

IFF's Scent Recovery Gains Traction as Fine and Consumer Fragrance Evolve in 2H 2026

Keep Reading

Keep Reading

IFF's Scent Recovery Gains Traction as Fine and Consumer Fragrance Evolve in 2H 2026

IFF Scent Recovery Gains Momentum in Q2 2026 with Second-Half Outlook

IFF's Scent Recovery Fueled by 2026 Q2 R&D Reboot; H2 Outlook and 2027 Plan

IFF’s Scent Recovery Driven by Fragrance Ingredients, R&D Push Toward 2027 in Q2 2026

IFF Scent Recovery Gains Momentum in Q2 2026, H2 Outlook and 2027 R&D Plan

IFF Scent Recovery Fueled by Fragrance Ingredients, Q2 2026 Outlook, and 2027 R&D Plan

IFF Scent Recovery Strengthens as Q2 2026 Highlights R&D Path to 2027

IFF Scent Recovery Gains Traction in Q2 2026, R&D Plan Sets 2027 Outlook

IFF Scent Recovery Gains Momentum in 2H, R&D Plan Targets 2027

IFF Scent Recovery Driven by Fragrance Ingredients; H2 Outlook and 2027 R&D Plan

IFF's Scent Recovery Fueled by Fragrance Ingredients Momentum and 2027 R&D Plan

IFF Q2 2026 Highlights on Scent Recovery, H2 Fragrance Outlook, and 2027 R&D Plan